Meeting ReportPoster - PhysicianPharm
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
Swayamjeet Satapathy, Bhagwant Mittal, Ashwani Sood and Anish Bhattacharya
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1311;
Swayamjeet Satapathy
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
Bhagwant Mittal
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
Ashwani Sood
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
Anish Bhattacharya
1Nuclear Medicine Postgraduate Institute of Medical Education & Research, Chandigarh Chandigarh India
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
Swayamjeet Satapathy, Bhagwant Mittal, Ashwani Sood, Anish Bhattacharya
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1311;
Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
Swayamjeet Satapathy, Bhagwant Mittal, Ashwani Sood, Anish Bhattacharya
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1311;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.